Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Double-blind, Randomised, Placebo Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of S1-221 Following Oral Administration

NCT07146945 is registered in ClinicalTrials.gov with Delphian Therapeutics Australia Pty, Ltd as lead sponsor.

NCT NCT07146945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07146945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Double-blind, Randomised, Placebo Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of S1-221 Following Oral Administration
Lead sponsor
Delphian Therapeutics Australia Pty, Ltd
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2025
Completion date
August 17, 2026
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants